Bio Path Holdings Inc (BPTH)

[wordlender]

Agreed. They lack focus.

BPTH could make a business model out of what they have been doing: identifying protein targets and handling all pre-clinical and early clinical trials. This would be a valuable service to big biotech firms looking to expand their pipelines. Prexigerbersen has sufficient data at this point that a deal could be made. Unfortunately, we have such little cash that any deal right now would be lopsided. I don’t see a viable alternative, though. We need cash and a partner that can commercialize our products. I don’t really know, but perhaps that cash and partnership would cost 90% of future prexigerbersen revenue, maybe more? At this point, I think that is fair and I think the market would respond very positively to that sort of a deal. Perhaps $25 -$35 million paid out as milestones are reached? That doubles our current market value and provides a viable path forward for the company.

BPTH is supposedly looking for partner(s). I pray that a partner is found soon.

Still holding long.